The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)
Psychogenic Polydipsia Psychogenic polydipsia (PPD) (also known as primary polydipsia) is excessive and volitional water intake commonly patients with severe mental illness and/or developmental disability
Policy noticed 1/1/2019 for effective date 4/1/2019
Compounded medications, while legal and legitimate, dont go through FDA approval processes
If you imagine a public health campaign to get more people onto AUD medication, it would be a stunning achievement if you were able to more than triple the usage rate over 5 years and that may be what has already happened inadvertently
Some 1 mL designs (especially tuberculin style or those labeled low dead space) have a plunger that extends into the tip to minimize wasted space